The report titled “Cancer Biomarkers Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall cancer biomarkers market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of multiple market segments based on type, type of cancer, type of profiling technologies, type of application, and different geographies. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of disease. Factors such as rising prevalence of cancer, increasing support from government and non-government organizations for cancer biomarkers research, aging population, and increasing use of biomarkers in the drug discovery and development process.
For the purpose of this study, the global cancer biomarker market is segmented on the basis of type into genetic biomarkers, epigenetic biomarkers, metabolic biomarkers, proteomic biomarkers, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
On the basis of type of cancer such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The global cancer biomarker market is also segmented on the basis of type of profiling technologies such as immunoassays, omics technologies, cytogenetics, imaging technologies, & bioinformatics. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The global cancer biomarker market is segmented on the basis of type of application such as into diagnostics, drug discovery & development, prognostics, risk assessment, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The geographical segmentation of cancer biomarkers market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.
The cancer biomarkers market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure Inc., Qiagen N.V., Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies Inc., Merck & Co. Inc., Hologic, Inc., and Becton Dickinson and Company among others.
In year 2016, proteomic biomarkers dominated the market by type due to exceptional market potential of protein biomarkers in diagnostics, prognostics, cancer detection and other clinical & therapeutic applications. In addition, increasing focus of pharmaceutical & biotechnology companies in research and development of protein biomarkers is expected to fuel the overall market growth. During the forecast period 2017 – 2025, epigenetics was observed as the fastest growing segment as it gained high acceptance in cancer diagnostics industry. The key factors driving the growth of epigenetics segment are high amount of research carried out by many players for the analysis of key epigenetic modification, and increasing collaboration between diagnostics and pharmaceutical companies for developing precise diagnosis and target specific treatment.
In year 2016, omics technologies accounted for the largest share of the cancer biomarkers market and also the fastest growing segment due to key driving factors such as increased adoption of advanced high throughput technologies in biomarker discovery and development and rising application of omics-based tests for cancer diagnosis and drug development process. In addition, incessant developments in high-throughput omics technologies are also backing the growth of this market, by rising the space of prospective biomarkers in cancer research.
In year 2016, breast cancer dominated the cancer biomarkers market by cancer type due to rising prevalence of disease, high awareness associated with early diagnosis, increasing public awareness with assistance of government and non-government organizations, and rising research and development activities in the field of breast cancer diagnosis. During the forecast period 2017 – 2025, lung cancer was observed as the fastest growing segment due to key driving factors such as rising prevalence of lung cancer due to increase in air pollution and frequent smoking observed in young generation.
Rising prevalence of cancer, increasing demand for efficient diagnosis techniques against cancer, developing research activities in the field of cancer biomarkers, and increasing awareness associated with early cancer diagnosis are the key factors driving the overall cancer biomarkers market. In year 2016, applications segment was dominated by diagnostics due to key driving factors such as increasing public awareness about the importance of early diagnosis of cancer and diagnostic biomarkers enable doctors to decide effective treatment alternatives.
In base year 2016, North America accounted for the largest share in global cancer biomarkers market due to key driving factors such as high prevalence of cancer, mounting healthcare expenditure leading to rise in demand for efficient diagnostic tests and health care services, and incessant technological advancements in the cancer biomarkers industry. According to the American Cancer Society, in 2017 about 190,500 cancer deaths in the US will be caused by cigarette smoking alone. An estimated 20% of all cancers diagnosed in the US are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition, and thus could also be prevented. During forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region in cancer biomarkers market due to rising prevalence and awareness of cancer, supportive government policies, market expansion by key market players, and rising application of biomarker tests for cancer diagnosis.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cancer Biomarkers market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Type
| |
Cancer
| |
Profiling Technologies
| |
Application
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
